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Papillary thyroid microcarcinomas (PTMCs) are the most common form of classic 
papillary thyroid carcinoma (PTC). PTMCs are typically discovered by fine-nee-
dle-aspiration biopsy (FNAB), usually with sensitive imaging studies, or are found 
during thyroid surgery in a patient without a previously known history of thyroid 
carcinoma. However, the definition of PTMC has not always been universally ac-
cepted, thus creating controversy concerning the diagnosis and treatment of 
PTMC. The aim of this review is to summarize the clinical features of PTMC and 
identify the widely differing opinions concerning the diagnosis and management 
of these small ubiquitous thyroid tumors. 
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BACKGROUND
Prior to 2003, papillary thyroid microcarcinomas (PTMC) was defined by the 
World Health Organization (WHO) as a tumor 1 cm or less in diameter1 but in 
2004 this definition transiently changed to a new classification requiring that 
PTMC tumor must also be found incidentally. At the same time, the 5th UICC (In-
ternational Union Against Cancer) and AJCC (American Joint Commission on 
Cancer) TNM staging systems-(Tumor),- (Node)-, (Metastasis), defined PTMC as 
T1, a tumor 1 cm or less in greatest dimension. However, in 2002 the 6th edition 
of the TNM staging system2 changed the definition of T1 to a tumor 2 cm or less 
in greatest diameter or limited to the thyroid, which altered both the WHO and 
TNM standards for PTMC to the extent that no prognostic definition for PTMC 
existed to predict the course of PTMC and the long-term outcome for an individu-
al patient.3 Much of these changes are related to the rising incidence rates of papil-
lary thyroid cancer (PTC), particularly in the form of PTMCs <1 cm.3 
CHANGING INCIDENCE RATES OF 
THYROID CANCER IN THE UNITED STATES
 
The incidence rates of PTC are growing at a faster rate than any other malignancy Ernest L. Mazzaferri
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rates increased 177% in men and 252% in women. The inci-
dence rates have also increased in children and adolescents at 
a rate of 1.1% per year in the U.S.7 and in England,8 and have 
increased at an even greater rate of 3% per year across Eu-
rope.9 Still, thyroid cancer remains a relatively rare tumor 
that represents only 2% of all cancers in the U.S.A.10  
Commentary
Thyroid cancer incidence rates have been increasing around 
the world, the cause of which is multifocal but also remains 
partially uncertain. The rise in PTMC has sparked a wide 
range of controversies beginning from about 1955, and 
thereafter has increased significantly.11-13 
THE RANGE OF PTMCS IN 
AUTOPSY STUDIES
Pazaitou-Panayiotou, et al.13 identified 24 autopsy studies 
that were performed in 1986 through 2005 during which 
7,663 autopsy cases of thyroid cancer were performed, and 
the prevalence rates of PTMC ranged from 2% to 35.6%, us-
ing tumor resection techniques ranging from 1-2 mm to 3-5 
mm, with the majority making 2-3 mm tissue resections 
(66%). A review of several other autopsy studies14 found that 
approximately one-third of adults have at least one PTMC 
The authors also identified 11 surgical series of patients 
treated for benign thyroid disease that had incidental coex-
istence with PTMC. The prevalence of PTMC ranged from 
1.3% to 21.6%, and the relationship between PTMC and 
thyrotoxicosis varied from 0.3% to 5.7%15,16 in surgical 
specimens, an association that varies among surgical se-
ries,17-19 and the risk of thyroid malignancy in multinodular 
goiter was comparable to that of solitary thyroid nodules. 
Commentary
Autopsy studies have played a key role in clinical decision-
making in patients with PTMCs. 
AUTOPSY STUDIES FROM THE USA 
ARMED FORCES INSTITUTE OF 
PATHOLOGY (AFIP)
Silliphant, et al.20 performed one of the largest and earliest 
analyses of autopsy studies in 1944 through 1958 from the 
AFIP among the more than 240,000 autopsy reports in 
in the USA and have been steadily rising according to the 
National Cancer Institute (NCI) Surveillance Epidemiology 
and End Results (SEER) program.4 
Hughes, et al.5 performed a retrospective study to evalu-
ate the effects of age on the influence of the increasing inci-
dence rates of PTC as reported in the NCI SEER database. 
From 1973 to 2006, the age group most commonly found 
to have PTC shifted from patients in their 30’s to patients in 
the 40-50 year-old group. However, by 1973, 60% of pa-
tients with PTC were younger than 45, and the majority 
continued to be younger patients until 1999. Thereafter, 
PTC became more common in patients older than 45, and 
by 2006, 61% were older than 45 years. From 1988 to 
2003, there has been an increasing incidence of PTC in all 
sizes and at all age groups, with the largest increase being 
in tumors <1 cm (PTMCs) in patients older than 45. How-
ever; 43% of tumors in patients older than 45 were <1 cm 
(PTMCs) and only 34% were younger than 45. Moreover, 
of the nearly 20,000 thyroid cancer cases in 2003, 24% 
were PTMCs in patients over the age of 45.5  
Commentary
Perhaps the most important finding in this study is that the 
number of PTCs <1 cm (PTMCs) are increasing in all ages 
but is disproportionally high in patients older than 45, and 
the changing patterns relating age and incidence rates have 
important prognostic and treatment implications for pa-
tients with PTMC. Yet how age affects the incidence rates 
of PTMC remains uncertain, but is nonetheless consistent 
in most countries.
THYROID CANCER RATES IN FIVE 
CONTINENTS 
 
Kilfoy, et al.6 analyzed the trends in the incidence of thyroid 
cancer across five continents (C15), over a 30-year period 
from 1973 to 2002 and has increased in 19 populations in the 
Americas, Asia, Europe, and Oceania, during which there 
was considerable variation in the thyroid cancer incidence 
rates in every continent but Africa. This trend has also been 
found in many other countries across Europe, Asia, Oceania, 
and South America, with the only countries reporting a de-
cline in thyroid cancer being Sweden (18%), Norway 
(5.8%), and Spain (25.9%) while there was an increase in 
Switzerland (5.3%) and France (155%) with the greatest in-
crease occurring in southern Australia where the incidence Managing Thyroid Microcarcinomas
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at approximately 0.5 deaths per 1,000,000. The authors con-
cluded that the increasing incidence of thyroid cancer in the 
USA is predominantly due to the increased detection of PT-
MCs, which the authors attribute to the “known existence of 
a substantial reservoir of subclinical cancer” and stable over-
all thyroid cancer mortality, suggesting to the authors that the 
increasing incidence of thyroid cancer reflects an enhanced 
detection of subclinical disease, not an increase in the true 
occurrence of thyroid cancer. The authors expressed the 
opinion that further studies will be needed to determine if a 
more cautious diagnostic approach is worthwhile and per-
haps simply providing follow-up for symptomatic thyroid 
nodules may be worthwhile, and thyroid cancers <1 cm 
could be classified as a normal finding. The authors identified 
a study by Vanderlann23 as a 50-year old study that patholo-
gists reported thyroid cancer-especially -PTC- was a com-
mon autopsy finding, despite the fact that the patients never 
had symptoms during lifetime. 
Commentary
A study conducted in Ontario, Canada by Kent, et al.24 report-
ed a similar increase of differentiated thyroid cancers ≤1 cm 
to 2 cm in diameter. Nonetheless, it is not likely that many pa-
tients would agree that a small thyroid cancer is a “normal 
phenomenon”, especially since we do not always know the 
growth rate of a patient’s PTMC without careful study and 
long term follow-up evaluation. Also, there are studies that 
challenge the concepts reported by Davies and Welch.
Enewold, et al.25 performed an analysis aimed at further 
understanding the rising thyroid cancer incidence rates that 
have been attributed to heightened medical surveillance and 
the use of improved diagnostic tests. The authors hypothe-
sized that if the increased incidence of thyroid cancer was 
entirely due to improved disease detection, then one would 
expect a greater number of small early-stage tumors, which 
in turn should decrease the incidence rates of large tumors 
of other histologies except for anaplastic cancer. Thyroid 
cancer incidence rates vary by sex and race/ethnicity, and 
these factors influence access to and utilization of health-
care. The authors thus examined thyroid cancer incidence 
rates by studying demographic and tumor characteristics of 
48,403 patients with thyroid cancer diagnosed during 1980-
2005 from the NCI SEER program. The incidence rates 
varied by the type of histology, sex, and race/ethnicity, and 
PTCs were the only histologic type for which incidence 
rates increased consistently among all racial/ethnic groups. 
Washington, DTC,20 among which 117 autopsy protocols 
of persons dying without suspicion of thyroid disease re-
vealed that only 45 (38%) of the protocols contained any 
reference to the thyroid gland. It was the authors’ opinion 
that the number of thyroid cancers found at autopsy is de-
pendent on the zeal of the prosector in searching for thyroid 
cancer. The validity of this idea was supported by the 1955 
work of Mortensen, et al.21 in which a painstaking search 
for thyroid cancer at autopsy found 28 primary cancers of 
the thyroid gland in 1,000 routine consecutive autopsies, 
and only 2 of the 28 cancers were recognized on a routine 
postmortem examination. When the same thyroid glands 
were examined more carefully, all grossly recognized nod-
ules were studied histologically, and 26 additional occult 
thyroid cancers were discovered, comprising an incidence 
rate of 2.8% in the 1,000 consecutive routine necropsies. 
Commentary
Autopsy studies have generated considerable controversy 
regarding the diagnosis and treatment of PTC and PTMC 
based upon the prevalence of these tumors in autopsy stud-
ies as a guide to forgo in vivo therapy for patients with PTC 
or PTMC, which is directly related to the rising incidence 
rates of thyroid cancer.
STUDIES EVALUATING THE RISING 
INCIDENCE OF PTC AND PTMC 
THYROID CANCER
Davies and Welch,22 performed a retrospective study in 2006 
that examined the trends in thyroid cancer incidence, histolo-
gy, tumor size and mortality. The study was performed on 
data in the NCI SEER program on thyroid cancer. The main 
finding was that the incidence of thyroid cancer increased 
from 3.6 per 100,000 in 1973 to 8.7 per 100,000-a 2.4-fold 
increase-[95% confidence interval (CI): 2.2-2.6]; p<0.001 for 
trend. There was no significant change in follicular, medul-
lary, and anaplastic cancer (p>0.20 for trend). The most im-
portant observation was that virtually the entire increase in 
thyroid cancer was the result of an increased incidence of 
PTC that advanced from 2.7 to 7.7 per 1,000,000, which is a 
2.9-fold increase (95%CI: 2.6-3.2: p<0.001 for trend). More-
over, between 1988 and 2002, 49% of the increase rates 
(95% CI: 47-51%) were from PTMCs <1 cm; and 87% 
(95% CI: 85-89%) were from thyroid cancers <2  cm. Thy-
roid cancer mortality was stable between 1973 through 2002 Ernest L. Mazzaferri
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creased incidence rates of all tumor sizes suggests that in-
creased diagnostic scrutiny is not the sole explanation for 
the high incidence of thyroid cancer, and other explanations 
including environmental influences and molecular path-
ways should be investigated.
OBSERVATION WITHOUT THERAPY 
FOR PATIENTS WITH PTMC ≤1 CM 
 
Ito, et al.27 hold the view that it is debatable whether pa-
tients with PTMC ≤1 cm should always undergo surgery, 
an opinion of the authors’ that is related to the high inci-
dence of occult PTCs that have been observed in autopsy 
studies. The authors accordingly proposed observation with-
out surgery as a treatment option for 732 patients, 162 of 
which (22%) opted for observation, while 570 others (78%) 
opted for immediate surgery. During follow-up of the ob-
servation group, 70% of tumors either did not change or de-
creased to their initial size. PTMCs enlarged by more than 
10 mm in 10.2%, and lymph-node metastases were found 
in the lateral compartment in 1.2% of patients. 
Ito and Miyauchi28 found in a 5-year follow-up study that 
6.7% of PTMCs enlarged 3.0 mm or more and lymph-node 
metastases were detectable in 1.7% of the patients. The au-
thors’ opinion was that observation without surgery could 
be an attractive alternative for patients with low-risk PTMC, 
but occult PTMC with lymph-node metastases or distant 
metastases show a worse prognosis, even in incidentally 
detected PTMCs.
Commentary
This study has a relative short-term follow-up and observa-
tion-group patients who developed tumors were switched 
to the surgery group. Also, the authors acknowledge that 
patients with PTMC may have aggressive disease requiring 
more intensive treatment. 
Noguchi, et al.29 performed a study of 2,070 patients with 
PTMC, which found that PTMCs larger than 6-10 mm re-
curred in 14% of the patients after 35 years of follow-up, as 
compared with 3.3% in patients with smaller tumors. Pa-
tients older than 55 years had a 40% recurrence rate during a 
30 year follow-up, which is a worse prognosis than that of 
younger patients who have recurrence rates of less than 10%. 
Also, extracapsular primary tumor invasion had a higher re-
Further analyses focused on 39,706 PTCs diagnosed during 
the period in which PTC rates increased most rapidly among 
women. Between 1992-1995 and 2003-2005, the PTC inci-
dence rates increased nearly 100% among White non-His-
panics and Black females but increased only 20% to 50% 
among White Hispanics, Asian/Pacific Islanders, and Black 
males. The increases were most rapid for localized tumor 
stage and small tumors. Still, the incidence rates also in-
creased for large tumors, regional tumors and distant stage. 
Since 1992-1995, half the overall increase in PTC rates 
was due to increasing rates of very small tumors (≤1 cm), 
i.e., PTMCs, and 30% to cancers 1.1 to 2 cm, and 20% to 
cancers >2 cm, and among White women, the incidence 
rate for cancers >5 cm almost equaled that of the smallest 
cancers. 
Commentary
The main findings in this study is the conclusion that medical 
surveillance and more sensitive diagnostic procedures cannot 
completely explain the observed increases in PTMC rates, 
and other possible explanations should be explored. Others 
have reached similar conclusions.
Chen, et al.26 performed a somewhat similar study with 
the goal of investigating the trends in the increasing inci-
dence of PTMC and follicular thyroid cancer (FTC) by tu-
mor size, age, race, and sex of differentiated thyroid cancer 
from 1988-2005 using the NCI SEER database. Trends in 
the incidence rates of PTC and FTC, race, age, sex, and pri-
mary tumor size <1.0 cm, and 1.0-2.9 cm, 3.0-3.9 cm, and 
>4 cm, and SEER-stage localized, regional, and distant tu-
mors were analyzed using joinpoint regression, which was 
reported as the annual percentage change (APC). 
The main findings were that incidence rates increased for 
tumors of all sizes. Among men and women of all ages, the 
highest rate of primary tumors was <1.0 cm (PTMC) among 
men in (1997-2005: APC, 9.9%) and women (1988-2005: 
APC, 8.6%). Significant increases also were observed for 
tumors >4 cm among men (1988-2005: APC, 3.7%) and 
women (1988-2005: APC, 5.70%) and for distant SEER 
stage disease among men (APC, 3.7%) and women (APC, 
3.6%). The incidence rates of differentiated thyroid cancers 
of all sizes increased between 1988 and 2005 in both men 
and women. 
Commentary
Enewold, et al.25 and Chen, et al.26 thus concluded that in-Managing Thyroid Microcarcinomas
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lignant. The author concluded that given the risk of malig-
nancy, patients with new thyroid lesions on a PET scan 
should have a tissue diagnosis if it will influence outcome 
and management. 
Commentary
Others have since confirmed the Cohen observations, and 
nowadays31-34 18FDG-PET/CT scans are utilized for a vari-
ety of reasons including screening for tumors, and are 
found by serendipity in the evaluation of benign thyroid tu-
mors and to perform accurate follow-up or to identify re-
current or persistent tumors. In other cases such as screen-
ing, there is concern regarding efficacy of this practice, and 
others suggest studies should be performed to produce posi-
tive and negative predictive values. Although PTMC is 
widely described as an indolent tumor, it may be associated 
with lymph-node metastases at the time of presentation,32 or 
with locoregional recurrences during follow-up, and distant 
metastases occur in extremely rare cases.32-34 All of which 
may be identified by18FDG-PET/CT. 
COMPARISON OF PROGNOSIS IN 
THYROID CANCERS 11-20 MM 
VERSUS ≤10 MM
Rossi, et al.35 performed this retrospective study with the 
aim of comparing the characteristics and outcomes of dif-
ferentiated thyroid cancers ≤10 cm and those with 11-20 
mm diameter. The study cohort, which was treated at the 
University of Ferrara Clinic in Italy, comprises 243 patients 
with tumors ≤1 cm that was PTMC and 183 were tumors 
11-20 mm that was almost exclusively PTCs that were stud-
ied. Mean patient age was >45 years in 69% and 69.9% in 
the PTMC and PTC groups, respectively (p=0.083), all of 
whom had total or near-total thyroidectomy. In addition, 131I 
remnant ablation was administered to 96% and 94.5% of 
the 2 groups, respectively (p=0.226). Bilateral/multifocal 
tumor was 32% and 30%, respectively (p=0.366). Intracap-
sular tumor extension (T1 stage) was 83% and 69.4%, re-
spectively (p=0.001). Extracapsular tumor extension (T3) 
at diagnosis was 17% and 30.6% respectively (p=0.001); and 
lymph-node-metastases at diagnosis were 13% and 25.1%, 
respectively (p=0.001); and distant metastases at diagnosis 
were 1.6% and 3.8%, respectively (p=0.095). However, there 
are problems with the 5th edition TNM stage as compared 
with the 6th edition TNM stage. 
currence rate, the majority of which were in the neck. During 
the interval between primary surgery and the first recurrence, 
there was 1 patient with lung metastases and 4 with bone me-
tastases and at the interval between the primary surgery and 
the second recurrence, 4 more patients had lung metastases, 
and 1 other had bone metastases and another had a mediasti-
nal tumor recurrence. Noguchi concluded that PTMC is sim-
ilar to larger PTCs with tumor characteristics and an age-
based recurrence rate that extends over many years, justifying 
long surveillance with ultrasonography after surgery. Also, 
there were significantly more metastases in the Noguchi 
study as that observed in the Ito study. 
Commentary
Noguchi had a substantially larger study cohort with a much 
longer follow-up than that in the Ito study, accounting for the 
major differences in outcome in the two studies. The Noguchi 
study underscores the extent of follow-up that is necessary in 
patients with PTMC, especially in patients who have had sur-
gery alone, particularly if the patient has had lymph-node me-
tastases, tumor extracapsular invasion or distant metastases.  
DIAGNOSTIC EFFECTS OF 18FDG-PET 
IN THE ANALYSIS OF PTMC
In 2001, Cohen, et al.30 was one of the first to identify thy-
roid incidentalomas by showing that these small thyroid tu-
mors often exhibit increased metabolic activity demonstrat-
ed by glucose uptake of 18Fluorodeoxyd-glucoseof18FDG-
PET scans with positron emission tomography (PET) and 
computed tomography (CT). This retrospective study re-
viewed all patients who had 18FDG-PET imaging from 
June 1, 1996, through March 15, 2001 and identified pa-
tients with newly diagnosed thyroid tumors. Thyroid inci-
dentaloma was defined as a thyroid tumor initially seen on 
18FDG-PET in a patient without a history of thyroid disease. 
A total of 102 of 4,525 18FDG-PET studies (2.3%) demon-
strated thyroid incidentalomas, and 85% (87of 102 patients) 
had no thyroid histology because of other malignancies, but 
15 patients had a thyroid biopsy, 7 (47%) with thyroid can-
cer, and 6 (40%) had nodular hyperplasia, 1 had thyroiditis 
and 1 had atypical cells of indeterminate origin. The aver-
age 18FDG-PET standardized uptake values (SUVs) were 
higher for malignant tumors than for benign lesions which 
occurred at a frequency of 2.3%. Among the thyroid inci-
dentalomas that were biopsied, 47% were found to be ma-Ernest L. Mazzaferri
Yonsei Med J   http://www.eymj.org   Volume 53   Number 1   January 2012 6
trasound-guided FNAB (US-FNAB) aimed at defining the 
rate of malignancy in patients with incidentally detected 
impalpable thyroid nodules and to evaluate the extent of 
disease in patients with cytology results suspicious of ma-
lignancy using US-FNAB. The authors identified the re-
cords of 267 patients who were studied from January 2000 
to December 2001 who had a total of 317 impalpable nod-
ules. The average nodule size was 0.9±0.3 cm, (range 0.2 
cm to 1.5 cm), all of which were impalpable. A total of 101 
(32%) US-FNAB cytology specimens were inadequate,139 
(44%) were benign, 29 (9%) were indeterminant, and 4 
(1%) were suspicious for follicular or Hürthle cell neoplasm, 
and 42 (13%) were suspicious or consistent with PTCs, and 
2 others had tumors measuring <0.5 cm, 22 with 0.5-1.0 cm 
i.e., PTMCs in most cases and 18 with 1-1.5 cm i.e., PTC in 
most cases. However, nodule size was not related to the 
probability of obtaining an adequate specimen for a cytolo-
gy diagnosis. Forty of 48 patients with suspicious or malig-
nant cytology had surgery, and the cytological diagnosis of 
PTC was histologically confirmed in all 35 patients. One of 
3 patients with a cytological diagnosis of follicular neo-
plasm had follicular cancer. Extrathyroidal tumor extension 
was observed in 36 patients with well-differentiated thyroid 
cancer; extrathyroidal extension was observed in 16 of 36 
patients (44%), and regional lymph node metastases were 
found in 16 of 36 patients (50%), and multifocal tumors were 
identified in 14 of 36 patients (39%). The rate of malignan-
cy in incidentally detected impalpable thyroid nodules was 
12% in a retrospective analysis in this group of patients. 
Among this subgroup, 25 of 36 (69%) patients either had 
extrathyroidal extension or regional lymph-node metastases 
and 14 of 36 (39%) had multifocal tumors at surgery, sug-
gesting that small tumor size alone does not assure low risk 
in incidentally identified thyroid cancers. The authors con-
cluded that US-FNAB is a useful diagnostic method in pa-
tients with impalpable thyroid nodules.
Commentary
This is one of the earlier studies that document the diagnos-
tic efficacy of ultrasound-guided-guided FNAB in PT-
MCs.37 The main finding was that a substantial number of 
patients either had extrathyroidal extension or regional 
lymph-node metastases, indicating that small tumor size 
alone does not guarantee low risk in incidentally identified 
thyroid cancer evaluated with US-guided FNAB, which is 
consistent with other studies38-41 that suggest PTMC can 
sometimes be an aggressive tumor.  
With the 5th TNM edition, 48 patients (26.22%) were stage 
I, but with the 6th edition, there were 125 Stage I patients 
(p<0.001); with the 5th edition, 47 patients (25.68%) were 
stage II, and with the 6th edition there were 4 Stage II patients 
(p<0.001); With the 5th edition, 85 patients (46.44%) were 
stage III, and with the 6th edition there were 50 (27.32%) 
stage III patients, (p<0.001). With the 5th edition, 3 patients 
(163%) were stage IV, and with the 6th edition there 4 
(2.18%) stage IV patients (p<0.276).
 By multivariate analysis, the presence of lymph node me-
tastases correlated with the diameter of the tumor (p<0.004): 
patients with cancer 11-20 mm in diameter had a 2.1-fold 
higher probability of having lymph-node metastases at the 
time of diagnosis. Also, capsular invasion significantly pre-
dicted lymph-node metastases at diagnosis: patients with 
capsular invasion had a 1.9-fold higher probability of hav-
ing lymph-node invasion at the time of diagnosis, and wom-
en had a threefold lower probability of having neck lymph-
node metastases at the time of diagnosis as compared with 
men (p<0.001).  
The prevalence of distant metastases thus did not differ be-
tween PTMCs ≤1 cm and 11-20 mm cancers. Also 133 pa-
tients (73%) with cancers 11-20 mm were disease-free 2 years 
after 131I therapy, and no recurrence was observed over 2-14 
years of follow-up. However, 41 patients (22%) with cancers 
11-20 mm (N1 or M1) required 2-4 years to become disease-
free. Neck lymph-node recurrence was observed in nine pa-
tients (4.9%) 4 months to 14 years after surgery and 131I thera-
py. Four patients (1.6%) with cancers ≤1 cm and 10 in 
diameter had cancer recurrence (p=0.05 compared with the 
11-20 mm cancers). The authors concluded that the presence 
of distant metastases at diagnosis and recurrence of disease 
during follow-up, cancers 11-20 mm in diameter seemed 
more aggressive than cancers ≤1 cm (p<0.05) and cancers 11-
20 mm seem more aggressive than those ≤1 cm than >10 cm. 
Commentary
This study suggests that PTMC and tumors 11-20 mm that 
have lymph-node metastases, tumor invasion, or extracap-
sular extension or with distant metastases should provoke 
considerable evaluation and appropriate therapy. 
SIZE ALONE DOES NOT GUARANTEE 
LOW RISK IN INCIDENTALOMAS
Nam-Goong, et al.36 performed a retrospective study of ul-Managing Thyroid Microcarcinomas
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jects were selected from a total of 1,676 patients with PTC 
who had surgery and follow-up from 1977 to 2006 at Chang 
Gung Medical Center in Taiwan. Among this large group of 
patients, 335 (20%) had PTMC defined as papillary cancer 
≤1 cm. All patients with PTMC were stratified as incidental 
(group I) or nonincidental (group II), and 209 group II pa-
tients were further categorized as intrathyroidal tumor 
(group IIA), or neck lymph node metastases or local re-
gional soft-tissue invasion (group IIB) or distant metastases 
(group IIC). Frozen sections obtained during surgery were 
evaluated to select the most significant nodules, and to 
identify the most invasive tumors in order to plan surgical 
dissection of the tumor. 
The main findings were that in group I, 105 of 126 (83%) 
patients received only subtotal thyroidectomy or lobecto-
my, and none died of thyroid cancer. The evaluation of his-
tology revealed 12 patients with multicentric PTMC (9.5%) 
in group I and 52 (24.9%) in group II (p<0.05) in the two 
groups respectively. In group II, 55 of the 209 patients 
(26.3%) were found to have extrathyroidal tumor involve-
ment. Two patients in group I had a relapse, and 20 in group 
II had a relapse by the end of follow-up. One patient in 
group IIB with local regional soft-tissue invasion and two 
in group IIC with distant metastases died of thyroid cancer, 
and nine out of ten patients in group IIC had a diagnosis of 
distant metastases before primary thyroid surgical treat-
ment. The authors concluded that subtotal thyroidectomy is 
effective surgical treatment for incidental PTMC, whereas 
nonincidental tumors require aggressive treatment that is 
essential for reducing the risk of cancer relapse or mortality.
Commentary
The authors make a strong case that patients with PTMC 
generally have an excellent prognosis and do not require 
adjuvant 131I therapy, whereas aggressive surgery and post-
operative 131I adjuvant therapy is indicated for patients with 
nonincidental PTMC with distant metastases or regional tu-
mor invasion or lymph-node metastases. 
PREDICTORS OF TUMOR RELAPSE 
AND FACTORS INFLUENCING 
DECISIONS TO TREAT PTMC 
Pellegriti, et al.42 performed a retrospective study aimed at 
identifying predictors of tumor relapse in small PTCs treat-
ed at the University Catanzaro, Italy between 1975 and 2001. 
THE IMPACT OF TUMOR SIZE AND 
OUTCOME OF PTMC
 
Bilimoria, et al.40 performed a retrospective study of the 
American College of Surgeons National Cancer Data Base 
(1985-1998) with the object of retrospectively examining 
52,173 patients with PTC to determine whether the extent 
of surgery affects the outcomes for PTC and whether tumor 
size thresholds exist for recurrence and mortality for PTC. 
The study found that total thyroidectomy results in lower 
recurrence and improved survival rates for PTCs ≥1.0 cm 
as compared with lobectomy. 
The specific outcomes were as follows: Ten-year tumor 
recurrence rates were 4.6% with tumors <1 cm, i.e., PTMCs, 
7.1% for tumors 1-1.9 cm, (1 cm or less=PTMC), and 8.6% 
for tumors 20-2.9 cm, (PTCs) 11.6% for tumors 30-3.9 cm, 
17.2% for tumors 4.0-8.0 cm and 24.8% for PTC tumors 
>8 cm. The 10-year cancer-specific mortality rates were 
significantly increased (p=0.040) only for tumors larger 
than 4.0 cm. Of the nearly 6,000 patients with tumors rang-
ing from 1-2 cm, (PTC) those treated with lobectomy expe-
rienced a 24% higher risk of recurrence and 49% had a 
higher risk of cancer death as compared with those treated 
with total thyroidectomy. Lastly, for patients with tumors 
≤1 cm (PTMC), those treated with lobectomy experienced a 
15% higher risk of recurrence and a 31% higher risk of can-
cer death (p=0.04) as compared with larger tumors.
Commentary  
This study demonstrates that PTC tumors ranging from 1-2 
cm in diameter may have a more aggressive behavior than 
has been readily apparent in studies of PTC tumors ≤1 cm 
alone.       
 
THE DIFFERENCE BETWEEN 
NONINCIDENTAL AND 
INCIDENTAL PTMC
Lin, et al.41 performed a retrospective study designed to test 
the hypothesis that less aggressive surgical treatment such 
as lobectomy or subtotal thyroidectomy is adequate therapy 
for incidental PTMC and whether total thyroidectomy fol-
lowed by 131I remnant ablation is effective for nonincidental 
PTMC. The study also investigated the clinical manifesta-
tions of incidental and nonincidental PTMC. The study sub-Ernest L. Mazzaferri
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PTC and the presence of lymph-node metastases.
Commentary
This study does not address whether near-total thyroidecto-
my or lobectomy should be performed to treat patients with 
small PTCs, although there were signs of tumor aggressive-
ness including multifocality (30%), lymph-node metastases   
(-30%), vascular invasion (4.7%) and distant metastases 
(2.7%), and 25.7% had persisting/relapsing disease, sug-
gesting that total thyroidectomy is warranted in this group 
of patients. 
USING CLINICAL CRITERIA TO 
IDENTIFY PATIENTS WITH PTMC
Durante, et al.43 performed a retrospective study at the Uni-
versity of Roma, Italy that attempted to define the optimal 
strategy for the management and long-term surveillance of 
very-low risk PTMC. The authors tested the hypothesis that 
clinical criteria could be used to identify patients with PTMC 
≤1 cm with very-low mortality or low risk of recurrence. 
Most PTMCs ≤1 cm diameter are indolent low-risk tumors, 
but some behave more aggressively. As a consequence, con-
troversies have erupted over the optimal postoperative sur-
veillance of patients with PTMC. The authors retrospec-
tively analyzed data from 312 consecutively diagnosed 
PTMCs in patients with T1N0M0 stage disease, with no 
family history of thyroid cancer, no history of head and 
neck irradiation, unifocal PTMC without extracapsular in-
volvement, and classic PTC histology. Additional inclusion 
criteria were complete follow-up data from surgery to at 
least 5 years after diagnosis. All 312 patients had been treat-
ed with near-total thyroidectomy and (44%) had 131I rem-
nant ablation, and all had a yearly follow-up with cervical 
ultrasonography and serum thyroglobulin, TSH, and anti-
thyroglobulin assays. During follow-up for 5-23 years, (me-
dian 6.7 yr), there were no deaths due to thyroid cancer or 
reoperations. In the first 6-12 months after surgery and last 
postoperative cervical sonograms were negative in all cas-
es. Final serum thyroglobulin levels were undetectable (<1 
ng/mL) and all patients treated with 131I and almost all 
(93%) of non-RAI patients. In this study, the yearly ultra-
sound examinations were consistently negative even in the 
76 patients (24.3%) that had follow-up for more than 10 
years. The authors concluded that in the vast majority 
(about 75%) of all patients with PTMC, effective postoper-
The study group comprised 299 patients who had surgery 
for PTC ≤1.5 cm. Near-total or total thyroidectomy was 
performed in 292 patients with PTC no larger than 1.5 cm 
and lobectomy was performed on seven patients. Persistent/
recurrent disease was found in 77 patients, and in 37 of these 
patients, the only sign of persistent tumor was an increased 
TSH-stimulated serum thyroglobulin (Tg). Ten patients had 
distant metastases, and 68 had locoregional metastases. All 
284 patients who had near-total or total thyroidectomy were 
examined after levothyroxine (LT4) withdrawal. Patients with 
low residual 131I neck uptake, (<3%) and with tumors at low 
risk according to TNM staging, neck ultrasonography and 
whole-body 131I scan were performed after 5 mCi (185 
MBq) 131I, and in 43 patients with residual cervical 131I up-
take (>3%) were treated with 30 mCi (1,110 MBq). Lastly, 
91 patients with TNM T4 and/or N1 tumor (5th edition of 
TNM) had postsurgical treatment with 100 mCi of 131I 
(3,700 MBq). Residual or metastatic tumor due to recurrent 
disease for at least 12 months after the first postsurgical 
evaluation, or due to persistent disease when a 131I whole-
body scan was positive with or without detectable serum 
Tg levels. Serum Tg <1 ng/mL at the first postsurgical eval-
uation during LT4 withdrawal was an accurate predictor of 
absence of relapse. 
The authors concluded that approximately one of four 
patients (25%) with PTC ≤1.5 cm develops relapsing/per-
sisting disease after surgery. Lastly, baseline histopathologi-
cal tumor characteristics and serum Tg levels off LT4 at first 
postsurgical evaluation accurately predicted the risk of tu-
mor relapse. One third of tumors were multifocal and near-
ly one fifth were bilateral. Extrathyroidal invasion was fre-
quent (20%) and 30.1% had locoregional metastases. Nine 
tumors were sclerosing variant of PTCs, and one was tall 
cell variant, and all the others were classic PTC. Distant 
metastases were present in only 8 patients (2.7%). Tumor   
≤1.0 cm vs. 1.1-15 cm was not predictive of relapse, and no 
patient died of thyroid cancer, but 14.4% had evidence of dis-
ease at their last follow-up. Although larger cancers (1.1-1.5 
cm) had a higher prevalence of signs of aggressiveness at 
presentation, there was no significant difference in the out-
come in PTMCs <1.0 cm. 
Multivariate analysis indicated that metastatic lymph-
node metastases at thyroidectomy are the most important 
predictors of persistent/recurrent disease, and was associat-
ed with nonincidental thyroid cancer, lymph-node metasta-
ses at presentation, and bilateral tumor. The development of 
distant metastases was associated with sclerosing variant Managing Thyroid Microcarcinomas
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agnosis and management of PTMC. The authors concluded 
that the recurrence rate for PTMC is low, in the range of 
3.9%, and in the authors’ view loboisthmusectomy is the 
treatment of choice for patients with PTMC when only one 
focus of cancer is found by a histologic diagnosis, and total 
thyroidectomy is the optimal treatment for patients with mul-
tiple foci, and 131I therapy was considered for each patient, 
according to prognostic factors that were taken into account 
in a well-articulated approach to PTMC.  
PTMC CAN BE AN AGGRESSIVE 
TUMOR REQUIRING MANAGEMENT 
SIMILAR TO PTC 
Page, et al.46 performed a retrospective 8-year study (1998-
2006) with the aim of highlighting the fact that PTMC can 
be an aggressive tumor requiring therapeutic management 
similar to that of other differentiated thyroid cancers. The 
study subjects were 187 surgical patients managed in Head 
and Neck surgery at the University Hospital of Amiens 
France. PTMC was found in 65 patients, 52 women and 10 
men mean of age 44.3 years (range 22-77 years). A total of 
41 PTMCs were considered to be aggressive tumors be-
cause of the presence of risk factors such as a tumor >5 
mm, multifocal PTMCs, capsular tumor invasion, vascular 
embolus, tumor extending beyond the thyroid capsule, and 
metastatic lymph-node metastases. All patients with aggres-
sive PTMC were treated with total thyroidectomy and 131I. 
Most of the unilateral lobectomies were primary or second-
ary total lobectomies as a function of the histology exami-
nation, and patients with aggressive PTMC were treated 
with total thyroidectomy and 131I. In addition, ipsilateral re-
current laryngeal and lateral cervical lymph-node dissec-
tions were performed in 10 patients, and ipsilateral cervical 
lymph-node dissection was performed in 6 patients and bi-
lateral recurrent laryngeal and lateral cervical lymph-node 
dissections were performed in 3 patients. No recurrence or 
metastases were observed after a multidisciplinary follow-
up ranging from 6 months to 8 years. The main findings were 
that PTMC was found in 62 patients, comprising 33 (16%) 
of all thyroid cancers. Unilateral nodules were found in 23 
patients, 1 nodule was found in 19, cases, 2 nodules in 4 cas-
es, and 3 bilateral nodules were found in 2 cases. Multinodu-
lar goiter was found in 32 patients, and Graves’ disease goiter 
was found in 5 patients. A total of 11 FNABs were per-
formed; 8 were positive (malignant tumors) and 3 were neg-
ative surveillance can be based exclusively on cervical ul-
trasound. The authors concluded that accurate risk stratifi-
cation can allow safe follow-up of most patients with 
PTMC with a less intensive, more cost-effective protocol. 
Cervical ultrasonography is the mainstay of this protocol, 
and negative findings at the first postoperative examination 
are highly predictive of positive outcomes.
Commentary
This is a carefully articulated protocol that can be used over 
an extensive time for as long as 10 years in some patients 
with PTMC; however whether such prolonged follow-up is 
necessary remains uncertain. 
THE GUSTAVE-ROUSSY INSTITUTE 
EXPERIENCE WITH PTMC 
Baudin, et al.44 performed this retrospective study of PTMC 
with the aim of investigating the independent factors associ-
ated with tumor recurrence in an effort to define therapeutic 
guidelines for the management of PTMC. The study sub-
jects were 281 patients, 207 women and 74 men, with dif-
ferentiated thyroid cancer ≤1 cm who had treatment and fol-
low-up at the Gustave-Roussy Institute in Paris.45 The 
mean±SD, age at initial surgery was 41.9±13.8 years, range 
6-75, and the mean duration of follow-up was 7.3±6.2 years, 
range 0.6-33.7 years. The latest outpatient visits occurred 
from 1995 for 64% and from 1991 for 90% of the patients. 
Eleven patients died of causes other than thyroid cancer by 
the end of the study. When lobectomy had been performed 
and PTMC was diagnosed after a histologic examination, 
thyroidectomy with or without neck lymph node dissection 
and 131I therapy were considered for each case, according to 
prognostic factors from this group was taken into account.45 
The main conclusion of the study was that the recurrence 
rate for PTMC was low (3.9%), and in the authors’ view, lo-
boisthmusectomy is the treatment of choice for patients with 
PTMC when only one focus of cancer is found histological-
ly, and total thyroidectomy is the optimal treatment for pa-
tients with multiple foci. Multivariate analysis found only 
two parameters that significantly influenced PTMC recur-
rence: the number of PTMC foci on pathologic examination 
(p<0.002) and the extent of initial thyroid surgery (p<0.01).
Commentary
This is one of the early studies that fully address the initial di-Ernest L. Mazzaferri
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roid capsule remains an exceptional parameter that can be 
evaluated by histopathological examination of a PTC 20 
mm or less in size as a pT1 or pT3 tumor. The authors cor-
related a BRAFV600E mutation with both clinical and patho-
logical features and the degree of neoplastic infiltration to 
redefine the reliability of the current system of risk stratifi-
cation in a large selected group of PTCs smaller than 20 
mm. The presence of BRAF mutations was examined in 
1,060 PTCs less than 20 mm divided into four types of neo-
plastic infiltration: 1) totally encapsulated; 2) not encapsu-
lated without thyroid capsule invasion; 3) thyroid capsule 
invasion; and 4) extrathyroidal extension.
The main results were that the overall frequency of the 
BRAFV600E mutation was 44.6%. Both univariate and multi-
variate analyses demonstrated that BRAFV600E mutations 
had a strong association with PTC variants such as classical 
PTC and tall cell variant, thyroid cancer size 11-20 mm, tu-
mor multifocality and absence of tumor capsule, extrathy-
roidal extension, lymph node metastasis, higher AJCC can-
cer stage, and younger patient age. In PTCs staged as pT1 
with thyroid capsule invasion, BRAFV600E mutation was sig-
nificantly higher than in pT1 tumors that did not invade the 
thyroid capsule (67.3% vs. 31.8%, respectively), p<0.0001. 
There was no statistically significant difference in BRAFV600E 
alterations between pT1 tumors with thyroid capsule inva-
sion and pT3 tumors, 67.3 and 67.5%, respectively.
The authors concluded that evaluation o f BRAFV600E sta-
tus would be useful even in pT1 tumors to improve risk strat-
ification and patient management, and PTCs <12 mm limited 
to the thyroid (pT1) are low-risk tumors, which in the ab-
sence of lymph-node metastases can be successfully treated 
with total thyroidectomy alone; however PTCs of the same 
size with extrathyroidal extension (pT3) have a higher like-
lihood of metastases and persistent/recurrence that requires 
more aggressive treatment. 
Commentary
The correlation between patient age and BRAFV600E mutation 
has been the subject of considerable controversy.37-39,50-56 
Lee, et al.55 performed this study as a result of the conflict-
ing data on the usefulness of BRAFV600E and as a conse-
quence performed a meta-analysis of BRAFV600E that includ-
ed 12 studies with a total of 1,168 patients in which the 
frequency of BRAFV600E mutation was 49%. The BRAFV600E 
mutation was found to be associated with PTC histologic 
subtype, the presence of extrathyroidal extension and high-
ative. In the 8 positive cases (12.9%), the existence of can-
cer was suspected before surgery, and in the other patients, 
the microcarcinomas were found coincidentally. A total of 
41 of 62 patients (66.13%) of all PTMCs were considered 
to have aggressive tumors. There were 65 patients in the 
group with PTMC ≤1 cm that was considered to be aggres-
sive because of several risk factors such as tumor >5 mm, 
multifocal PTMCs, tumor capsular invasion, vascular em-
bolus, tumor extension beyond the thyroid capsule and 
lymph-node metastases. Of the 62 patients, 25 (40.32%) 
had PTMC, 15 had multifocal tumors (24.19%), respective-
ly, 24 had thyroid capsular invasion (38.71%), 13 had lymph-
node metastases (20.97%), respectively and 3 had vascular 
embolus (4.84%); however, the most frequent risk factors 
were thyroid capsular invasion and tumors with the largest 
diameter >5 mm.
The authors concluded that total thyroidectomy is the sur-
gical treatment of choice for the management of PTMCs, al-
though no consensus has been reached concerning lymph-
node surgery, and it appears to be performed only in the 
presence of lymphadenopathy on medical imaging or is de-
tected during surgery. 
Commentary
This is a long-term study in which the authors have achieved 
their goal of highlighting the fact that PTMC can be an ag-
gressive tumor requiring therapeutic management similar to 
that of other differentiated thyroid cancers. Several other 
studies have found that PTMC >5 mm, thyroid capsular in-
vasion, vascular emboli, tumor extending beyond the thy-
roid capsule, lymphadenopathy, and organ metastases may 
occur with PTMC.44-49   
BRAFV600E AND THE CLINICAL, 
PATHOLOGICAL, AND PROGNOSTIC 
FEATURES OF PTMC AND OVERT PTC
Basolo, et al.48 performed this study with the aim of retro-
spectively correlating BRAFV600E mutation with different 
clinical and pathological features in a large homogeneous 
series of PTCs 20 mm or smaller, and in addition, the au-
thors also investigated the relationship between BRAFV600E 
and the degree of neoplastic infiltration of PTCs smaller 
than 20 mm to redefine the reliability of the risk stratifica-
tion system for PTCs smaller than 20 mm.  
As the degree of neoplastic infiltration beyond the thy-Managing Thyroid Microcarcinomas
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molecular characteristics of PTMC and overt PTC. 
The major results were as follows: the prevalence of ex-
trathyroidal invasion (52.2%) and initial nodal metastasis 
(34.9%) in patients with PTMC was unexpectedly high and 
almost as high as that for patients with PTC (72.4% and 
51.8%, respectively). The rate of recurrent or persistent dis-
ease did not differ between patients with PTMC and PTC. 
The rate of recurrent or persistent disease, was 6.1% vs. 
14.1%; 53.4 vs. 84.2-month follow-up n=98 vs. 647; (cor-
rected p=112). The frequency of BRAF(V600E) mutation was 
similar in patients with PTMC and PTC (65.6% vs. 67.2%). 
Immunohistochemical staining showed no different expres-
sion pattern according to the tumor size. These results sug-
gest that PTMC is not an occult cancer and it can act like 
larger PTC. It is the authors’ opinion is that PTMC should 
not be underestimated in practice.
Commentary 
This is a major study that has clinical ramifications concern-
ing the diagnosis and treatment of PTMC and PTCs, and per-
haps most importantly, this study indicates that PTMC and 
PTC are an expression of the same tumor. 
HIGHLIGHT SUMMARY 
 
Clinical features that affect treatment, follow-up and 
outcome of PTMC 
• Patient age affects the incidence rates of PTC and 
PTMC  
• Autopsy studies have had a negative influence on the 
choice of therapy in patients with PTMC 
• A 5-year follow-up of PTMC ≤1 cm without surgery is 
possible, but over time often requires surgery 
• A 35-year follow-up of PTMC ≤1 cm may identify re-
gional and distant metastases, and relapses 
• 11-22 mm PTCs are likely to have a worse prognosis 
than PTMCs ≤10 mm
• 18FDG-PET scans are effective for screening and detect-
ing recurrences and metastases, but may create manage-
ment dilemmas leading to unnecessary procedures and pa-
tient anxiety
• Small tumor size alone does not always assure low risk 
in incidentally identified thyroid cancers 
• Incidental thyroid tumors usually require little or no 
therapy whereas non-incidental thyroid tumors usually re-
quire vigorous treatment
er clinical stage, but was not associated with age, sex, race, 
or tumor size, but the authors concluded that effect of the 
BRAFV600E mutation on the poor prognosis of PTC was ap-
parent in the meta-analysis, and the authors concluded that   
their study confirms the status of BRAFV600E that may be 
used as an important prognostic marker of patients with 
PTC and may be useful even in pT1 tumors that are impor-
tant prognostic markers of patients with PTC.55-58
Park, et al.57 performed this retrospective study with the 
aim of assessing the high recurrence rates of PTMC ≤1 cm 
in what is typically considered to have a benign course dur-
ing a patients’ lifetime, thus prompting the authors to per-
form this retrospective study at Seoul National University 
Hospital, Seoul, Korea, aimed at analyzing the clinicopatho-
logical features, long-term prognosis, and molecular charac-
teristics of BRAFV600E mutation. The study subjects were 175 
men and 975 women, mean age 45.6±13.3 years that had to-
tal thyroidectomy for PTC between 1983 and 2004. The 
study comprised 1,150 patients with PTC, 868 with PTC >1 
cm and 279 with PTMC ≤1 cm, which is generally regarded 
as an incidental finding that is present in up to 30% or 40% 
of surgical or autopsy cases.60-64
 Although PTMC ≤1 cm is generally considered to have 
a lifetime course, studies now report recurrence rates up to 
20%,31,32,35,43 and several cases of distant metastases with fa-
tal outcome have been described in patients with PTMC.64-71 
However, there are significant differences in the demograph-
ic and pathologic findings and prognosis between incidental 
PTMCs and those found incidentally at autopsy which are 
found in up to 30 to 40% of autopsy studies.49,50,54 PTMCs 
diagnosed by imaging studies68 include small PTCs that 
might represent an early phase in the development of overt 
PTCs >1 cm. Still, only a few studies have reported the 
clinicopathologic characteristics of PTMCs.70-76 
The authors of this study point out there is a particularly 
high frequency of activating mutations in the BRAF kinase 
gene BRAF(V600E) mutation in patients with PTC, which was 
described in Koreans.70 The BRAF(V600E) mutation was found 
to be associated with old age, male sex, lymph-node metas-
tases, and multifocal tumors.71 The authors were motivated 
to further study the characteristics of PTMCs by analyzing 
the BRAFV600E mutation, and the pathological findings and 
clinical outcomes between patients with PTMC and PTC to 
further investigate the clinical significance of recently de-
tected PTMCs. Also investigated were the expression of 
molecular markers associated with PTC that compared the Ernest L. Mazzaferri
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